Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine
•Allergy to vaccines is rare but has a heavy impact amidst mass vaccination campaigns.•History-based patient triaging helps mitigating allergy risk.•BNT162b2 vaccine can safely be administered to high-risk allergic subjects. Among 6146 hospital employees, 118 subjects with severe allergic background...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2021-10, Vol.39 (44), p.6464-6469 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6469 |
|---|---|
| container_issue | 44 |
| container_start_page | 6464 |
| container_title | Vaccine |
| container_volume | 39 |
| creator | Yacoub, Mona-Rita Cucca, Valentina Asperti, Chiara Ramirez, Giuseppe A. Della-Torre, Emanuel Moro, Matteo Zandalasini, Camilla Di Napoli, Davide Ambrosio, Alberto Signorelli, Carlo Colombo, Sergio Beretta, Luigi Ciceri, Fabio Zangrillo, Alberto Dagna, Lorenzo |
| description | •Allergy to vaccines is rare but has a heavy impact amidst mass vaccination campaigns.•History-based patient triaging helps mitigating allergy risk.•BNT162b2 vaccine can safely be administered to high-risk allergic subjects.
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis.
Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule.
13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis.
Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients. |
| doi_str_mv | 10.1016/j.vaccine.2021.09.048 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2578759027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21012391</els_id><sourcerecordid>2580460008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-dfcfb905fc1e1c8c7697b5f212e0ba7a3404bb6db39164ee1359700e3f6148913</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVoIG7Sn1AQ9JLLbma0H1qdShvcphDaiwO5Ca08suWuV460NvjfR8Y-9dLTwPC8w7wPY58RSgRsHzblwVjrRyoFCCxBlVB3V2yGnawK0WD3gc1AtHVRI7zesI8pbQCgqVDNWD93zltjjzw4bng0kw-jGbgZViH6ab3lU-AmJUop7waKqyOPPv3lfuS7DNM4JR7Jkj_4ccWnNfHvvxfYil7wy1d37NqZIdGny7xlLz_mi8en4vnPz1-P354LW0mYiqWzrlfQOIuEtrOyVbJvnEBB0Btpqhrqvm-XfaWwrYmwapQEoMq1WHcKq1t2f767i-FtT2nSW58sDYMZKeyTFo3sZKNAyIx--QfdhH3MvU9UB3Wb_XSZas6UjSGlSE7vot-aeNQI-mReb_Sloz6Z16B0Np9zX885ym0PnqJONouytPTZ1KSXwf_nwju7uo4m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580460008</pqid></control><display><type>article</type><title>Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Yacoub, Mona-Rita ; Cucca, Valentina ; Asperti, Chiara ; Ramirez, Giuseppe A. ; Della-Torre, Emanuel ; Moro, Matteo ; Zandalasini, Camilla ; Di Napoli, Davide ; Ambrosio, Alberto ; Signorelli, Carlo ; Colombo, Sergio ; Beretta, Luigi ; Ciceri, Fabio ; Zangrillo, Alberto ; Dagna, Lorenzo</creator><creatorcontrib>Yacoub, Mona-Rita ; Cucca, Valentina ; Asperti, Chiara ; Ramirez, Giuseppe A. ; Della-Torre, Emanuel ; Moro, Matteo ; Zandalasini, Camilla ; Di Napoli, Davide ; Ambrosio, Alberto ; Signorelli, Carlo ; Colombo, Sergio ; Beretta, Luigi ; Ciceri, Fabio ; Zangrillo, Alberto ; Dagna, Lorenzo</creatorcontrib><description>•Allergy to vaccines is rare but has a heavy impact amidst mass vaccination campaigns.•History-based patient triaging helps mitigating allergy risk.•BNT162b2 vaccine can safely be administered to high-risk allergic subjects.
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis.
Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule.
13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis.
Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.09.048</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Algorithms ; Allergies ; Anaphylaxis ; Asthma ; Coronaviruses ; COVID vaccine ; COVID-19 ; COVID-19 vaccines ; Drug allergy ; Drug dosages ; Fever ; Hypersensitivity ; Immunization ; Mast cell disorders ; Medical personnel ; Molecular weight ; mRNA ; mRNA vaccines ; Patients ; Questionnaires ; Risk groups ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Tryptase ; Vaccination ; Vaccines</subject><ispartof>Vaccine, 2021-10, Vol.39 (44), p.6464-6469</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-dfcfb905fc1e1c8c7697b5f212e0ba7a3404bb6db39164ee1359700e3f6148913</citedby><cites>FETCH-LOGICAL-c370t-dfcfb905fc1e1c8c7697b5f212e0ba7a3404bb6db39164ee1359700e3f6148913</cites><orcidid>0000-0002-7687-7648 ; 0000-0003-2417-0410 ; 0000-0001-8168-8174 ; 0000-0002-2889-366X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2580460008?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Yacoub, Mona-Rita</creatorcontrib><creatorcontrib>Cucca, Valentina</creatorcontrib><creatorcontrib>Asperti, Chiara</creatorcontrib><creatorcontrib>Ramirez, Giuseppe A.</creatorcontrib><creatorcontrib>Della-Torre, Emanuel</creatorcontrib><creatorcontrib>Moro, Matteo</creatorcontrib><creatorcontrib>Zandalasini, Camilla</creatorcontrib><creatorcontrib>Di Napoli, Davide</creatorcontrib><creatorcontrib>Ambrosio, Alberto</creatorcontrib><creatorcontrib>Signorelli, Carlo</creatorcontrib><creatorcontrib>Colombo, Sergio</creatorcontrib><creatorcontrib>Beretta, Luigi</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Zangrillo, Alberto</creatorcontrib><creatorcontrib>Dagna, Lorenzo</creatorcontrib><title>Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine</title><title>Vaccine</title><description>•Allergy to vaccines is rare but has a heavy impact amidst mass vaccination campaigns.•History-based patient triaging helps mitigating allergy risk.•BNT162b2 vaccine can safely be administered to high-risk allergic subjects.
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis.
Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule.
13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis.
Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients.</description><subject>Algorithms</subject><subject>Allergies</subject><subject>Anaphylaxis</subject><subject>Asthma</subject><subject>Coronaviruses</subject><subject>COVID vaccine</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Drug allergy</subject><subject>Drug dosages</subject><subject>Fever</subject><subject>Hypersensitivity</subject><subject>Immunization</subject><subject>Mast cell disorders</subject><subject>Medical personnel</subject><subject>Molecular weight</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Patients</subject><subject>Questionnaires</subject><subject>Risk groups</subject><subject>Safety</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Tryptase</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1rGzEQhkVoIG7Sn1AQ9JLLbma0H1qdShvcphDaiwO5Ca08suWuV460NvjfR8Y-9dLTwPC8w7wPY58RSgRsHzblwVjrRyoFCCxBlVB3V2yGnawK0WD3gc1AtHVRI7zesI8pbQCgqVDNWD93zltjjzw4bng0kw-jGbgZViH6ab3lU-AmJUop7waKqyOPPv3lfuS7DNM4JR7Jkj_4ccWnNfHvvxfYil7wy1d37NqZIdGny7xlLz_mi8en4vnPz1-P354LW0mYiqWzrlfQOIuEtrOyVbJvnEBB0Btpqhrqvm-XfaWwrYmwapQEoMq1WHcKq1t2f767i-FtT2nSW58sDYMZKeyTFo3sZKNAyIx--QfdhH3MvU9UB3Wb_XSZas6UjSGlSE7vot-aeNQI-mReb_Sloz6Z16B0Np9zX885ym0PnqJONouytPTZ1KSXwf_nwju7uo4m</recordid><startdate>20211022</startdate><enddate>20211022</enddate><creator>Yacoub, Mona-Rita</creator><creator>Cucca, Valentina</creator><creator>Asperti, Chiara</creator><creator>Ramirez, Giuseppe A.</creator><creator>Della-Torre, Emanuel</creator><creator>Moro, Matteo</creator><creator>Zandalasini, Camilla</creator><creator>Di Napoli, Davide</creator><creator>Ambrosio, Alberto</creator><creator>Signorelli, Carlo</creator><creator>Colombo, Sergio</creator><creator>Beretta, Luigi</creator><creator>Ciceri, Fabio</creator><creator>Zangrillo, Alberto</creator><creator>Dagna, Lorenzo</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7687-7648</orcidid><orcidid>https://orcid.org/0000-0003-2417-0410</orcidid><orcidid>https://orcid.org/0000-0001-8168-8174</orcidid><orcidid>https://orcid.org/0000-0002-2889-366X</orcidid></search><sort><creationdate>20211022</creationdate><title>Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine</title><author>Yacoub, Mona-Rita ; Cucca, Valentina ; Asperti, Chiara ; Ramirez, Giuseppe A. ; Della-Torre, Emanuel ; Moro, Matteo ; Zandalasini, Camilla ; Di Napoli, Davide ; Ambrosio, Alberto ; Signorelli, Carlo ; Colombo, Sergio ; Beretta, Luigi ; Ciceri, Fabio ; Zangrillo, Alberto ; Dagna, Lorenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-dfcfb905fc1e1c8c7697b5f212e0ba7a3404bb6db39164ee1359700e3f6148913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Allergies</topic><topic>Anaphylaxis</topic><topic>Asthma</topic><topic>Coronaviruses</topic><topic>COVID vaccine</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Drug allergy</topic><topic>Drug dosages</topic><topic>Fever</topic><topic>Hypersensitivity</topic><topic>Immunization</topic><topic>Mast cell disorders</topic><topic>Medical personnel</topic><topic>Molecular weight</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Patients</topic><topic>Questionnaires</topic><topic>Risk groups</topic><topic>Safety</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Tryptase</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yacoub, Mona-Rita</creatorcontrib><creatorcontrib>Cucca, Valentina</creatorcontrib><creatorcontrib>Asperti, Chiara</creatorcontrib><creatorcontrib>Ramirez, Giuseppe A.</creatorcontrib><creatorcontrib>Della-Torre, Emanuel</creatorcontrib><creatorcontrib>Moro, Matteo</creatorcontrib><creatorcontrib>Zandalasini, Camilla</creatorcontrib><creatorcontrib>Di Napoli, Davide</creatorcontrib><creatorcontrib>Ambrosio, Alberto</creatorcontrib><creatorcontrib>Signorelli, Carlo</creatorcontrib><creatorcontrib>Colombo, Sergio</creatorcontrib><creatorcontrib>Beretta, Luigi</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Zangrillo, Alberto</creatorcontrib><creatorcontrib>Dagna, Lorenzo</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yacoub, Mona-Rita</au><au>Cucca, Valentina</au><au>Asperti, Chiara</au><au>Ramirez, Giuseppe A.</au><au>Della-Torre, Emanuel</au><au>Moro, Matteo</au><au>Zandalasini, Camilla</au><au>Di Napoli, Davide</au><au>Ambrosio, Alberto</au><au>Signorelli, Carlo</au><au>Colombo, Sergio</au><au>Beretta, Luigi</au><au>Ciceri, Fabio</au><au>Zangrillo, Alberto</au><au>Dagna, Lorenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine</atitle><jtitle>Vaccine</jtitle><date>2021-10-22</date><risdate>2021</risdate><volume>39</volume><issue>44</issue><spage>6464</spage><epage>6469</epage><pages>6464-6469</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Allergy to vaccines is rare but has a heavy impact amidst mass vaccination campaigns.•History-based patient triaging helps mitigating allergy risk.•BNT162b2 vaccine can safely be administered to high-risk allergic subjects.
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis.
Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule.
13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis.
Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.vaccine.2021.09.048</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7687-7648</orcidid><orcidid>https://orcid.org/0000-0003-2417-0410</orcidid><orcidid>https://orcid.org/0000-0001-8168-8174</orcidid><orcidid>https://orcid.org/0000-0002-2889-366X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2021-10, Vol.39 (44), p.6464-6469 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2578759027 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Algorithms Allergies Anaphylaxis Asthma Coronaviruses COVID vaccine COVID-19 COVID-19 vaccines Drug allergy Drug dosages Fever Hypersensitivity Immunization Mast cell disorders Medical personnel Molecular weight mRNA mRNA vaccines Patients Questionnaires Risk groups Safety Severe acute respiratory syndrome coronavirus 2 Statistical analysis Tryptase Vaccination Vaccines |
| title | Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A54%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20a%20rational%20algorithm%20to%20assess%20allergy%20risk%20in%20patients%20receiving%20the%20BNT162b2%20vaccine&rft.jtitle=Vaccine&rft.au=Yacoub,%20Mona-Rita&rft.date=2021-10-22&rft.volume=39&rft.issue=44&rft.spage=6464&rft.epage=6469&rft.pages=6464-6469&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.09.048&rft_dat=%3Cproquest_cross%3E2580460008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580460008&rft_id=info:pmid/&rft_els_id=S0264410X21012391&rfr_iscdi=true |